| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Finer Jeffrey, Director
Received 18,500 shares by exercise or conversion ($51.1K) · Sold 18,500 shares ($807K) |
| 16 Nov 2026 | 144 |
| 13 Nov 2026 |
Form 4: Ezekowitz Alan, Director
Sold 81,820 shares ($3.93M) |
| 12 Nov 2026 | 144 |
| 12 Nov 2026 | 144 |
| 12 Nov 2026 | 144 |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 |
| 04 Nov 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.2 Pioneering a New Era of GPCR Drug Discovery Corporate Presentation November 2026 Nasdaq: SEPN © 2026 SEPTERNA |
| 19 Oct 2026 |
Form 4: Bhatt Elizabeth, President and COO
Received 4,000 shares by exercise or conversion ($27.2K) · Sold 4,000 shares ($150K) |
| 01 Oct 2026 | 144 |
| 01 Oct 2026 | 144 |
| 10 Sep 2026 |
Form 4: Patni Rajiv, Chief Medical Officer
Granted 275,000 Stock Option (Right to Buy) |
| 03 Sep 2026 |
Form 3: Patni Rajiv, Chief Medical Officer
No securities owned |
| 03 Sep 2026 |
Form 4: Long Daniel D., SVP, Drug Discovery
Received 3,333 shares by exercise or conversion ($9.2K) · Sold 3,333 shares ($126K) |
| 25 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
SOUTH SAN FRANCISCO, Calif. – August 25, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patn... |
| 14 Aug 2026 |
Form 4: Third Rock Ventures V, L.p., 10% owner and 5 others
Acquired 147,200 shares (Open Market Sale) ($7.4M) |
| 14 Aug 2026 | SCHEDULE 13D/A |
| 14 Aug 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others
Sold 1,493,000 shares ($63.5M) |
| 14 Aug 2026 | SCHEDULE 13G/A |
Loading...